Submental Fat Reduction with Injectables: Patient Selection and Injection Protocol

Submental fat reduction — the non-surgical treatment of the area beneath the chin that patients refer to as a 'double chin' — is the most evidence-supported, most precisely understood, and most widely practised injectable lipolytic application in aesthetic medicine. The zone has a defined fat compartment with reasonably predictable anatomy, a pharmaceutical-grade active agent with multiple Phase 3 RCTs behind it (deoxycholic acid, branded as Kybella/Belkyra), and a well-characterised safety profile built from extensive clinical experience.

It is also the application where the consequences of poor patient selection and imprecise technique are most concentrated. The submental zone is adjacent to the marginal mandibular nerve, the anterior neck vasculature, and the hyoid-strap muscle complex — all of which can be injured by incorrectly placed product. And the pronounced post-treatment inflammatory response, if not thoroughly communicated before treatment, reliably generates alarmed patients and complaint calls.

This guide focuses on the two clinical activities that most determine submental lipolytic outcomes: patient selection and injection technique. It is part of Celmade's Lipolytic content cluster — for the complete mechanism and category overview, see the Complete Lipolytic Injectables Guide. Browse Celmade's lipolytic range for CE-marked Korean DCA and PC/DCA products.

Understanding Submental Anatomy Before You Inject

The submental zone contains a defined subcutaneous fat compartment — but it is surrounded by structures that are sensitive to deoxycholic acid's non-selective cytolytic activity. The injection protocol's safe zone boundaries are defined by these anatomical neighbours:

The four safe zone boundaries that protect all of the above structures simultaneously are covered in detail below. Practitioners new to submental lipolytics should study the anatomy with a dedicated anatomical atlas before their first treatment session — written descriptions are an insufficient substitute for three-dimensional anatomical understanding of this zone.

The Submental Assessment: What to Evaluate at Consultation

The submental assessment at consultation does three things: confirms the nature of the patient's concern (is it fat, skin laxity, or both?), determines the appropriate treatment approach, and sets the parameters of realistic outcome expectations.

Step 1: Determine What the Patient Is Presenting With

Not all submental concerns are submental fat. The area can appear full or poorly contoured for several distinct reasons that require different treatments:

Step 2: Pinch Test for Fat vs Skin Laxity

The pinch test is the most clinically useful single assessment at submental consultation. Ask the patient to extend their chin (look slightly upward) to stretch the submental skin. Then:

•        Pinch the skin between thumb and forefinger: If you can grasp a substantial fold of compressible tissue (> 1cm), subcutaneous fat is present. This is your treatment target.

•        Assess what remains between the fingers: A thick, compressible fold indicates significant fat. A thin, almost skin-only fold indicates minimal fat and predominantly skin laxity — a poor candidate for lipolytic treatment alone.

•        Skin snap: After pinching, release and observe how quickly the skin recoils. Good recoil (< 1 second) indicates reasonable skin elasticity — fat reduction will be followed by natural skin contraction. Slow recoil (> 2 seconds) indicates poor elasticity — skin tightening will be needed alongside or after fat reduction.

Step 3: Photograph in Standard Positions

Submental lipolytic treatment requires photography in at least three positions for adequate pre/post comparison:

•        Frontal view at rest: Head level, neutral expression.

•        Lateral view (left and right): True 90-degree profile, head level. The lateral view is the most revealing for submental fat profile — this is where the full contour of the submental bulge is visible.

•        Extended chin (Frankfort horizontal): Head slightly extended, chin projected forward. This view shows the maximum submental extent and the degree of skin laxity under extension.

Step 4: Palpate the Treatment Zone

Before marking, palpate the submental zone carefully:

•        Palpate for lymph nodes: Submental and submandibular lymph nodes — if enlarged or tender, do not treat. Lymphadenopathy in this zone has multiple causes including dental infection, upper respiratory infection, and less commonly, lymphoma. A swollen lymph node is not a normal anatomical variant and should be investigated before any treatment.

•        Palpate for thyroid: Confirm normal thyroid position and size. An unusually high thyroid or goitre would change the inferior safe zone boundary.

•        Palpate the mandibular border: Confirm the inferior border of the mandible — your superior injection boundary is 1–1.5cm below this line. In patients with significant submental fat, the mandibular border may be difficult to palpate — take time to locate it accurately.

Patient Selection: The Ideal Candidate and the Exclusions

Confident submental lipolytic outcomes come from seeing the right patients. The following framework covers both who to select and who to decline:

The Ideal Submental Lipolytic Patient

Patients Who Are Not Appropriate

The Injection Protocol in Depth

The submental injection protocol requires methodical preparation, precise marking, and consistent technique. Deviation from the established protocol increases risk without clinical benefit.

Equipment Required

The Safe Zone: Boundaries Explained

Before the injection grid is drawn, the safe zone boundaries must be marked precisely. Marking is done with the patient sitting upright (not supine) — submental fat shifts in the supine position and the mandibular border is easier to palpate with the patient sitting.

Drawing the Injection Grid

Within the marked safe zone, draw a 1cm dot grid:

•        Starting from the midline, mark dots at 1cm intervals horizontally across the zone

•        Mark dots at 1cm intervals vertically down the zone

•        All dots must be within the marked boundaries — no dot outside the safe zone, even if this means the grid is incomplete at the edges

•        Count the total dots before starting — this determines the total product volume needed for the session and confirms the treatment field is appropriately covered

•        Typical dot count: 20–50 depending on the size of the fat deposit and the treatment zone dimensions

The Injection Procedure

1.     Position the patient supine once marked. The sitting marks are now on the skin — inject with the patient reclined. Instruct the patient not to move their head or swallow during injections.

2.     Apply ice for 2 minutes over the entire marked zone. Then inject immediately while anaesthesia from ice is active. (EMLA should already have been applied and removed 45–60 minutes before.)

3.     Insert the needle perpendicular to the skin (90 degrees) at the first dot. Advance until the needle tip is in the subcutaneous fat — typically 1–1.5cm below the skin surface. The resistance should be soft (fat). If you feel firm resistance, you are in the platysma — withdraw 2–3mm.

4.     Aspirate briefly. Gentle aspiration before each injection reduces (but does not eliminate) vascular injection risk. Blood in the syringe = vascular placement. Withdraw, compress for 30 seconds, and re-inject at an adjacent point 0.5cm away.

5.     Inject 0.2ml slowly and steadily. Avoid rapid bolus injection. Slow delivery reduces immediate discomfort and may reduce the risk of product escaping the intended tissue plane.

6.     Withdraw and apply pressure. After each point, immediate gentle pressure with sterile gauze for 5–10 seconds. This reduces bruising and helps contain product at the injection site.

7.     Work systematically through the grid. Work row by row or zone by zone to ensure all marked points are treated without double-treating or missing any point.

8.     Post-injection: ice for 10–15 minutes. Apply ice packs to the entire treatment zone immediately after completing all injections. This is the most valuable post-treatment comfort measure.

Recognising and Managing Marginal Mandibular Nerve Injury

Marginal mandibular nerve injury is the most feared complication of submental lipolytic treatment and the one that most requires proactive recognition and management. Every practitioner administering submental lipolytics must be able to recognise this complication immediately and know the management pathway:

Assessing Results and Planning Subsequent Sessions

The assessment at week 6–8 following each session is the most important clinical appointment in the lipolytic treatment course. It determines whether further sessions are needed and builds or sustains patient confidence in the treatment:

•        Compare standardised photographs: Show the patient the before/after comparison in all three positions. Patients regularly underestimate their improvement because they see their face daily in a non-standardised way. The standardised lateral profile comparison is typically the most dramatic and satisfying.

•        Palpate the remaining fat: The amount of compressible tissue on the pinch test provides objective assessment of remaining fat volume.

•        Assess skin quality: Has the skin contracted appropriately as the fat reduced, or is there residual laxity? If laxity is apparent, introduce the conversation about skin tightening as a next step once fat reduction is complete.

•        Decide on further sessions: If meaningful fat remains and the patient wants further improvement: schedule the next session at the same protocol. If the patient has achieved their desired result: move to final assessment and discuss maintenance. Most patients require 2–4 sessions.

Combining Submental Lipolytics with Other Treatments

•        Botulinum toxin to the platysma and neck: Toxin to the platysma bands can be administered at the same session as lipolytic treatment or at a separate session. Platysma banding and horizontal neck lines often coexist with submental fat — treating both in a coordinated plan addresses the full picture. Korean botulinum toxin products (Botulax, Nabota) from Celmade's botulinum toxin range are appropriate for neck and platysma applications.

•        Chin filler for projection: Chin filler to improve chin projection reduces the visual prominence of the submental-to-chin contour relationship. Some patients benefit from both fat reduction and chin projection — the combination addresses both the fat volume and the structural framing of the submental zone. Treat in separate sessions; chin filler can precede or follow lipolytic treatment.

•        HIFU or RF tightening for skin laxity: For patients with mixed fat and skin laxity, plan lipolytic treatment first. Once the fat reduction result is fully established (8–12 weeks post-final session), add HIFU or RF tightening to address any residual skin laxity that the fat removal has made more apparent.

•        PDRN for skin quality: For patients concerned about the skin quality of the submental zone alongside its contour, PDRN can be administered to the overlying skin once the lipolytic treatment sessions are complete and fully resolved. Separate sessions; minimum 6–8 weeks after the final lipolytic session.

Key Takeaways

•        Know your anatomy before you inject — the marginal mandibular nerve and anterior neck structures are the primary safety risks. The safe zone boundaries are defined by their locations.

•        Confirm it is fat, not laxity — the pinch test and snap test are the two most important physical assessment tools at consultation. A patient with laxity without fat is not a lipolytic candidate.

•        Mark in the sitting position — fat shifts supine and the mandibular border is harder to palpate. All marking must be done sitting upright.

•        A systematic 1cm grid within the safe zone — consistency of coverage is the technical standard. Every marked dot is treated; no unmarcked areas are injected.

•        Aspirate before each injection — reduces but does not eliminate vascular injection risk. Non-negotiable standard.

•        The 6–8 week review is when results are assessed — not 2 weeks. Significant swelling through week 3 is normal and expected. Assessment before week 6 is premature.

•        Korean CE-marked DCA from Celmade is the accessible clinical standard — pharmaceutical-grade, full documentation, 30–50% lower wholesale cost. Browse the lipolytic collection.

For related guides: Complete Lipolytic Injectables Guide, Botulinum Toxin: Masseter, Neck, and Jaw Applications. Browse lipolytic products and botulinum toxin products.

Frequently Asked Questions

How many submental fat injection sessions are needed?

Most patients require 2–4 sessions spaced 6–8 weeks apart. The number depends on the initial fat deposit volume, the patient's individual inflammatory clearance response, and the result achieved after each session. Some patients with small deposits achieve their desired result after 1–2 sessions; patients with larger deposits may need up to 4–6 sessions. Each session should be assessed at week 6–8 before deciding on the next — treating before full resolution of the previous session's effect makes result assessment impossible.

Is injectable chin fat removal painful?

The injection session itself is moderately uncomfortable rather than severely painful — topical anaesthesia (EMLA) applied 45–60 minutes before treatment and ice immediately before injection significantly reduce discomfort. The post-injection burning sensation from the deoxycholic acid is the most intense moment — patients describe a burning/stinging sensation in the submental zone that persists for 15–30 minutes and then reduces as the local anaesthetic effect accumulates. The 48–72 hours following treatment with peak swelling is the most uncomfortable period post-session — ibuprofen (if not contraindicated) is appropriate for symptom management.

Will the fat come back after treatment?

The fat cells destroyed by deoxycholic acid are permanently destroyed — they do not regenerate. In this sense, the fat in the treated zone does not 'come back'. However, if the patient gains significant weight after treatment, the remaining fat cells in the treated zone and adjacent zones can expand, reducing the improvement. Patients who maintain a stable weight after treatment maintain their results long-term. Injectable lipolytic treatment produces the best long-term outcomes in patients who are at or near their healthy weight and are not planning significant weight changes.

What should I tell patients about the swelling?

Tell patients everything before the first treatment — not after seeing the swelling. Specifically: significant swelling will develop within hours and will peak at 48–72 hours; the area will look and feel larger and firmer than before treatment for the first 2–3 weeks; this is expected and is the sign the treatment is working; ice packs and anti-inflammatories (if not contraindicated) help manage discomfort; the result cannot be assessed for 6–8 weeks; plan nothing important for the 48–72 hours after each session. A patient who has been told all of this in advance will manage the post-treatment phase calmly and arrive at the 6-week review expecting good news — which is typically what they get.

Can injectable lipolytics be used for submental skin laxity?

No — injectable lipolytics destroy fat, not skin. If the primary submental concern is skin laxity rather than fat, lipolytic treatment is not appropriate and will potentially worsen the appearance by removing the fat that is currently providing some support to the overlying lax skin. For skin laxity in the submental and neck zone, HIFU, RF tightening (Morpheus8 or similar), or surgical neck lift are the appropriate treatment modalities.